

Dennis A Hesselink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8077079/publications.pdf>

Version: 2024-02-01

147
papers

5,324
citations

94269

37
h-index

102304

66
g-index

147
all docs

147
docs citations

147
times ranked

5189
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 245-254.	2.3	580
2	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	1.0	374
3	Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2. <i>American Journal of Transplantation</i> , 2005, 5, 987-994.	2.6	278
4	The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2014, 53, 123-139.	1.6	186
5	Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management. <i>Transplantation Reviews</i> , 2015, 29, 78-84.	1.2	161
6	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genes. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 545-556.	2.3	153
7	A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 2085-2096.	2.6	129
8	Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials. <i>American Journal of Transplantation</i> , 2013, 13, 1253-1261.	2.6	117
9	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 339-348.	0.7	110
10	A high inpatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. <i>Transplant International</i> , 2016, 29, 1158-1167.	0.8	108
11	Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 555-565.	1.5	106
12	Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1225-1236.	1.5	95
13	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	1.0	89
14	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. <i>Pharmacogenomics</i> , 2005, 6, 323-337.	0.6	82
15	Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. <i>Nature Reviews Nephrology</i> , 2014, 10, 725-731.	4.1	77
16	COVID-19 in solid organ transplant recipients: a single-center experience. <i>Transplant International</i> , 2020, 33, 1099-1105.	0.8	71
17	Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 327-330.	1.1	70
18	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. <i>Clinical Pharmacokinetics</i> , 2017, 56, 963-975.	1.6	69

#	ARTICLE	IF	CITATIONS
19	Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 153.	2.2	63
20	Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 317-321.	2.3	61
21	The Pharmacogenetics of Calcineurin Inhibitor-Related Nephrotoxicity. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 387-393.	1.0	59
22	Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. <i>Clinical Pharmacokinetics</i> , 2018, 57, 191-207.	1.6	58
23	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 601-615.	1.1	56
24	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S57-S69.	1.0	54
25	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 313-322.	0.7	52
26	Preoperative right heart hemodynamics predict postoperative acute kidney injury after heart transplantation. <i>Intensive Care Medicine</i> , 2018, 44, 588-597.	3.9	52
27	Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. <i>British Journal of Surgery</i> , 2017, 104, 804-813.	0.1	51
28	The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1868-1873.	0.4	49
29	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. <i>Clinical Pharmacokinetics</i> , 2018, 57, 475-489.	1.6	48
30	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 360-368.	1.0	48
31	Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation. <i>PLoS ONE</i> , 2016, 11, e0150826.	1.1	46
32	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. <i>Frontiers in Pharmacology</i> , 2017, 8, 358.	1.6	44
33	Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of Tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 459-465.	1.0	43
34	Characterization of ectopic lymphoid structures in different types of acute renal allograft rejection. <i>Clinical and Experimental Immunology</i> , 2018, 192, 224-232.	1.1	42
35	Acute kidney injury in imported <i>Plasmodium falciparum</i> malaria. <i>Malaria Journal</i> , 2015, 14, 523.	0.8	40
36	Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. <i>American Journal of Kidney Diseases</i> , 2017, 69, 796-804.	2.1	40

#	ARTICLE	IF	CITATIONS
37	Characterization of donor and recipient CD8+ tissue-resident memory T cells in transplant nephrectomies. <i>Scientific Reports</i> , 2019, 9, 5984.	1.6	40
38	The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function. <i>PLoS ONE</i> , 2017, 12, e0170806.	1.1	39
39	Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 515-525.	1.0	39
40	Improved long-term survival in Dutch heart transplant patients despite increasing donor age: the Rotterdam experience. <i>Transplant International</i> , 2015, 28, 962-971.	0.8	36
41	Acute kidney injury and 1-year mortality after left ventricular assist device implantation. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 116-123.	0.3	33
42	The effects of renal transplantation on circulating dendritic cells. <i>Clinical and Experimental Immunology</i> , 2005, 140, 384-393.	1.1	31
43	Validation of an LC-MS/MS Method to Measure Tacrolimus in Rat Kidney and Liver Tissue and Its Application to Human Kidney Biopsies. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 617-623.	1.0	31
44	The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 812-822.	1.1	30
45	Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. <i>Transplantation Direct</i> , 2017, 3, e129.	0.8	30
46	Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis. <i>Transplant International</i> , 2020, 33, 1626-1642.	0.8	30
47	Personalized immunosuppression in elderly renal transplant recipients. <i>Pharmacological Research</i> , 2018, 130, 303-307.	3.1	29
48	Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. <i>PLoS ONE</i> , 2018, 13, e0196552.	1.1	29
49	The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection. <i>Frontiers in Immunology</i> , 2019, 10, 748.	2.2	29
50	Incidence of end-stage renal disease after heart transplantation and effect of its treatment on survival. <i>ESC Heart Failure</i> , 2020, 7, 533-541.	1.4	29
51	Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2003, 32, 151-155.	0.6	28
52	Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 3143-3156.	2.6	28
53	Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 921-936.	1.5	28
54	Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. <i>PLoS ONE</i> , 2016, 11, e0148604.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. <i>Pharmacogenomics</i> , 2016, 17, 1737-1740.	0.6	26
56	Implementation of donation after circulatory death kidney transplantation can safely enlarge the donor pool: A systematic review and meta-analysis. <i>International Journal of Surgery</i> , 2021, 92, 106021.	1.1	26
57	Experience with cyclosporine in endogenous uveitis posterior. <i>Transplantation Proceedings</i> , 2004, 36, S372-S377.	0.3	25
58	Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 641.	2.2	25
59	Usage of Tacrolimus and Mycophenolic Acid During Conception, Pregnancy, and Lactation, and Its Implications for Therapeutic Drug Monitoring: A Systematic Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 518-531.	1.0	25
60	Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. <i>Transplantation Reviews</i> , 2015, 29, 224-230.	1.2	24
61	Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of <i>de novo</i> anti-HLA donor-specific antibodies in kidney transplant recipients. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1323-1331.	1.3	24
62	Exploring the neuroregenerative potential of tacrolimus. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1047-1057.	1.3	24
63	Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 169-178.	2.3	24
64	Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2019, 33, e4416.	0.8	23
65	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. <i>Clinical Epigenetics</i> , 2016, 8, 116.	1.8	22
66	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 665-670.	1.0	22
67	The use of cyclosporine in renal transplantation. <i>Transplantation Proceedings</i> , 2004, 36, S99-S106.	0.3	21
68	Costimulation Blockade in Kidney Transplant Recipients. <i>Drugs</i> , 2020, 80, 33-46.	4.9	21
69	Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. <i>Clinical Pharmacokinetics</i> , 2018, 57, 877-893.	1.6	20
70	Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 71-79.	0.8	20
71	Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1918-1929.	1.1	20
72	Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 945-946, 171-177.	1.2	18

#	ARTICLE	IF	CITATIONS
73	Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. <i>Frontiers in Immunology</i> , 2020, 11, 1972.	2.2	18
74	Development and Validation of Hematocrit Level Measurement in Dried Blood Spots Using Near-Infrared Spectroscopy. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 351-357.	1.0	18
75	Neutrophil gelatinase-associated lipocalin (NGAL) predicts the occurrence of malaria-induced acute kidney injury. <i>Malaria Journal</i> , 2016, 15, 464.	0.8	17
76	Uremia-Associated Premature Aging of T Cells Does Not Predict Infectious Complications After Renal Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 2324-2333.	2.6	17
77	Pre-operative proteinuria in left ventricular assist devices and clinical outcome. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 124-130.	0.3	17
78	Lung Transplantation in Gaucher Disease. <i>Chest</i> , 2016, 149, e1-e5.	0.4	16
79	Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. <i>American Journal of Cardiology</i> , 2017, 120, 2221-2225.	0.7	16
80	Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. <i>Pharmacological Research</i> , 2018, 130, 308-315.	3.1	16
81	A drug transporter for all ages? <i>ABC1</i> and the developmental pharmacogenetics of cyclosporine. <i>Pharmacogenomics</i> , 2008, 9, 783-789.	0.6	15
82	Measurement of Cyclosporine A in Rat Tissues and Human Kidney Transplant Biopsies—A Method Suitable for Small (<1 mg) Samples. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 688-693.	1.0	15
83	Alemtuzumab as Antirejection Therapy. <i>Transplantation Direct</i> , 2016, 2, e83.	0.8	15
84	Hepatitis E virus genotype 3 infection in a tertiary referral center in the Netherlands: Clinical relevance and impact on patient morbidity. <i>Journal of Clinical Virology</i> , 2016, 74, 82-87.	1.6	15
85	High Inpatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2329-2337.	0.5	15
86	A 2020 Banff Antibody-Mediated Injury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation—a cohort study. <i>Transplant International</i> , 2021, 34, 488-498.	0.8	15
87	Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients. <i>Transplantation Direct</i> , 2019, 5, e418.	0.8	14
88	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. <i>Clinical Pharmacokinetics</i> , 2020, 59, 591-603.	1.6	14
89	Practicability of Pharmacogenetics in Transplantation Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 262-264.	2.3	13
90	Surgical Safety and Efficacy of Third Kidney Transplantation in the Ipsilateral Iliac Fossa. <i>Annals of Transplantation</i> , 2019, 24, 132-138.	0.5	13

#	ARTICLE	IF	CITATIONS
91	Protein and calorie restriction may improve outcomes in living kidney donors and kidney transplant recipients. <i>Aging</i> , 2020, 12, 12441-12467.	1.4	13
92	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	1.2	12
93	Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 54-55, 101756.	1.0	12
94	Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial. <i>Scientific Reports</i> , 2017, 7, 15135.	1.6	11
95	Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. <i>PLoS ONE</i> , 2018, 13, e0201113.	1.1	11
96	Iron deficiency after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1976-1985.	0.4	11
97	Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	11
98	Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection. <i>Frontiers in Immunology</i> , 2020, 11, 1332.	2.2	10
99	Donor-specific ELISPOT assay for predicting acute rejection and allograft function after kidney transplantation: A systematic review and meta-analysis. <i>Clinical Biochemistry</i> , 2021, 94, 1-11.	0.8	10
100	The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy. <i>Annals of Transplantation</i> , 2018, 23, 577-590.	0.5	9
101	Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation. <i>Clinical Biochemistry</i> , 2022, 101, 9-15.	0.8	9
102	Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms. <i>Transplantation Direct</i> , 2018, 4, e350.	0.8	8
103	Utility of immunohistochemistry with C3d in C3 glomerulopathy. <i>Modern Pathology</i> , 2020, 33, 431-439.	2.9	8
104	Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?. <i>Transplantation</i> , 2020, 104, 2478-2486.	0.5	8
105	Urinary Extracellular Vesicles Are a Novel Tool to Monitor Allograft Function in Kidney Transplantation: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10499.	1.8	8
106	Detection of a rare <i>CYP3A4</i> variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. <i>Pharmacogenomics</i> , 2018, 19, 305-310.	0.6	7
107	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms in living donors do not impact clinical outcome after kidney transplantation. <i>Pharmacogenomics</i> , 2018, 19, 895-903.	0.6	7
108	Acquired haemophilia A after alemtuzumab therapy. <i>Haemophilia</i> , 2020, 26, e337-e339.	1.0	7

#	ARTICLE	IF	CITATIONS
109	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 431-435.	1.0	7
110	Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients. <i>Pharmacological Research</i> , 2021, 167, 105565.	3.1	7
111	Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection. <i>Scientific Reports</i> , 2021, 11, 12445.	1.6	7
112	A systematic review and meta-analysis of enzyme-linked immunosorbent spot (ELISPOT) assay for BK polyomavirus immune response monitoring after kidney transplantation. <i>Journal of Clinical Virology</i> , 2021, 140, 104848.	1.6	7
113	Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation Trial. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 606-614.	1.0	7
114	A Novel High-throughput Droplet Digital PCR-based Indel Quantification Method for the Detection of Circulating Donor-derived Cell-free DNA After Kidney Transplantation. <i>Transplantation</i> , 2022, 106, 1777-1786.	0.5	7
115	A randomized crossover study comparing different tacrolimus formulations to reduce inpatient variability in tacrolimus exposure in kidney transplant recipients. <i>Clinical and Translational Science</i> , 2022, 15, 930-941.	1.5	7
116	Co-inhibitory profile and cytotoxicity of CD57+PD-1 ^{hi} T cells in end-stage renal disease patients. <i>Clinical and Experimental Immunology</i> , 2018, 191, 363-372.	1.1	6
117	Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study. <i>Clinical Epigenetics</i> , 2021, 13, 32.	1.8	6
118	Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen in combination with everolimus in de novo renal transplantation in Elderly patients. <i>BMC Nephrology</i> , 2021, 22, 208.	0.8	6
119	Improving long-term outcomes of kidney transplantation: The pressure is on. <i>Netherlands Journal of Medicine</i> , 2014, 72, 248-50.	0.6	6
120	The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. <i>Transplant International</i> , 2004, 17, 495-504.	0.8	5
121	The use of freeze-dried blood samples affects the results of a dried blood spot analysis. <i>Clinical Biochemistry</i> , 2022, 104, 70-73.	0.8	5
122	Association Between the Intracellular Tacrolimus Concentration in CD3+ T Lymphocytes and CD14+ Monocytes and Acute Kidney Transplant Rejection. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 625-632.	1.0	5
123	High Tacrolimus Inpatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 369-376.	1.0	5
124	Renal transplantation—reducing risk and improving outcome. <i>Nature Reviews Nephrology</i> , 2015, 11, 72-73.	4.1	4
125	Oxalate deposition in renal allograft biopsies within 3 months after transplantation is associated with allograft dysfunction. <i>PLoS ONE</i> , 2019, 14, e0214940.	1.1	4
126	The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 313-316.	0.4	4

#	ARTICLE	IF	CITATIONS
127	Circulating endothelial cells transiently increase in peripheral blood after kidney transplantation. <i>Scientific Reports</i> , 2021, 11, 8915.	1.6	4
128	A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 523-535.	0.6	4
129	Serum magnesium, hepatocyte nuclear factor 1 β genotype and post-transplant diabetes mellitus: a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 176-183.	0.4	3
130	Pitfalls in the Detection of Donor-Derived Cell-Free DNA in Transplant Recipients. <i>Clinical Chemistry</i> , 2021, 67, 1030-1032.	1.5	3
131	Immune Subsets From Ficoll Density Gradient Separation in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1319.	0.8	3
132	Advanced in vitro Research Models to Study the Role of Endothelial Cells in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 607953.	2.2	2
133	Care for the organ transplant recipient on the intensive care unit. <i>Journal of Critical Care</i> , 2021, 64, 37-44.	1.0	2
134	Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1155-1164.	2.3	2
135	Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1273-1287.	0.8	2
136	Fifteen-year survival of a polycystic kidney transplant. <i>Transplant International</i> , 2015, 28, 870-871.	0.8	1
137	Targeted Proteomic Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 243-248.	1.0	1
138	Clinical Relevance of Arteriolar C4d Staining in Patients With Chronic-active Antibody-mediated Rejection: A Pilot Study. <i>Transplantation</i> , 2020, 104, 1085-1094.	0.5	1
139	A comparison of two different analytical methods for donor-derived cell-free DNA quantification. <i>Clinical Biochemistry</i> , 2021, 96, 82-84.	0.8	1
140	The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. <i>Transplant International</i> , 2004, 17, 495-504.	0.8	1
141	Validation of a dried blood spot method to measure tacrolimus concentrations in small volumes of mouse blood. <i>Bioanalysis</i> , 2022, 14, 441-449.	0.6	1
142	When a zero mismatch is no longer superior. <i>Transplant International</i> , 2015, 28, 398-400.	0.8	0
143	Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 466.	2.2	0
144	Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review. <i>Transplantation Direct</i> , 2021, 7, e717.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Progress of Immunosuppressive regimen after kidney transplantation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY52-1.	0.0	0
146	Seen from the moon we are all the same size: Deceased donation in the Netherlands. Netherlands Journal of Medicine, 2016, 74, 282-4.	0.6	0
147	Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients. Pharmacogenomics, 0, , .	0.6	0